Article Information
History
- December 16, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Marcus J. Bolton1,
- Jordan T. Ort1,
- Ryan McBride2,
- Nicholas J. Swanson3,
- Jo Wilson3,
- Moses Awofolaju1,
- Allison R. Greenplate4,
- Elizabeth M. Drapeau1,
- Andrew Pekosz3,
- James C. Paulson2 and
- Scott E. Hensley1,*
- 1Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 2Department of Molecular Medicine and Department of Immunology and Microbiology, Scripps Research Institute, La Jolla, California, USA
- 3Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
- 4Institute for Immunology and Immune Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- ↵*Correspondence: hensley{at}pennmedicine.upenn.edu
Posted December 16, 2021.
Antigenic and virological properties of an H3N2 variant that will likely dominate the 2021-2022 Northern Hemisphere influenza season
